Items where Author is "Wouters, Olivier J."

Number of items: 55.
Article
  • Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective. (2025) Chan, Mei Xuan Jessalyn and Wouters, Olivier J. and Chan, Hui Yun and Terblanche, Petro and Premsri, Nakorn and Kim, Jerome H. and Lim, John C.W. and Tan-Koi, Wei Chuen and Jit, Mark
  • Integrating price benchmarks and comparative clinical effectiveness to inform the medicare drug price negotiation program. (2024) Sullivan, Sean D. and Wouters, Olivier J. and Cousin, Emma M. and Kirihennedige, Ayuri S. and Hernandez, Inmaculada picture_as_pdf
  • Sales revenues for new therapeutic agents approved by the United States Food and Drug Administration from 1995 to 2014:a retrospective study. (2024) Wouters, Olivier J. and Kesselheim, Aaron S. and Kuha, Jouni and Luyten, Jeroen picture_as_pdf
  • Product hopping in the drug industry — lessons from Albuterol. (2022) Wouters, Olivier J. and Feldman, William B. and Tu, S. Sean picture_as_pdf
  • Association of research and development investments with treatment costs for new drugs approved from 2009 to 2018. (2022) Wouters, Olivier J. and Berenbrok, Lucas A. and He, Meiqi and Li, Yihan and Hernandez, Inmaculada picture_as_pdf
  • The challenges of regulating artificial intelligence in healthcare:comment on “Clinical decision support and new regulatory frameworks for medical devices: are we ready for it? - a viewpoint paper”. (2022) McKee, Martin and Wouters, Olivier J. picture_as_pdf
  • Challenges in ensuring global access to COVID-19 vaccines:production, affordability, allocation, and deployment. (2021) Wouters, Olivier J. and Shadlen, Kenneth C and Salcher-konrad, Maximilian and Pollard, Andrew J and Larson, Heidi J and Teerawattananon, Yot and Jit, Mark picture_as_pdf
  • Association between provincial income levels and drug prices in China over the period 2010–2017. Shi, Wunan and Wouters, Olivier J. and Liu, Gordon and Mossialos, Elias and Yang, Xiuyun picture_as_pdf
  • Availability and coverage of new drugs in 6 high-income countries with health technology assessment bodies. Wouters, Olivier J. and Naci, Huseyin and Papanicolas, Irene picture_as_pdf
  • Brexit and the European Medicines Agency—what next for the Agency and UK drug regulators? Wouters, Olivier J. and Hervey, Tamara and McKee, Martin
  • Comparing generic drug markets in Europe and the United States:prices, volumes, and spending. Wouters, Olivier J. and Kanavos, Panos and McKee, Martin
  • Differential legal protections for biologics vs. small-molecule drugs in the US. Wouters, Olivier J. and Vogel, Matthew and Feldman, William B. and Beall, Reed F. and Kesselheim, Aaron S. and Tu, S. Sean picture_as_pdf
  • Divergent COVID-19 vaccine policies:policy mapping of ten European countries. van Kessel, Robin and Forman, Rebecca and Milstein, Ricarda and Mastylak, Alicja and Czabanowska, Katarzyna and Czypionka, Thomas and Durand-Zaleski, Isabelle and Hirche, Anja and Krysinska-Pisarek, Magdalena and Roberts, Bjelle and Maynou-Pujolras, Laia and Torbica, Aleksandra and Wang, Yuxi and Vrangbæk, Karsten and Wouters, Olivier J. and Mossialos, Elias picture_as_pdf
  • Drug prices negotiated by medicare vs US net prices and prices in other countries. Wouters, Olivier J. and Sullivan, Sean D. and Cousin, Emma M. and Gabriel, Nico and Papanicolas, Irene and Hernandez, Inmaculada picture_as_pdf
  • Early chronic kidney disease: diagnosis, management and models of care. Wouters, Olivier J. and O'Donoghue, Donal J. and Ritchie, James and Kanavos, Panos and Narva, Andrew S.
  • Errors in source data for study of drug development costs. Wouters, Olivier J. and McKee, Martin and Luyten, Jeroen
  • Health Technology Assessment in the US—a word of caution—reply. Wouters, Olivier J. and Naci, Huseyin and Papanicolas, Irene
  • Health care after the Great Recession: financing options for sustainable and high-quality health systems. Kanavos, Panos and Wouters, Olivier J.
  • High drug prices are not justified by industry’s spending on research and development. Angelis, Aris and Polyakov, Roman and Wouters, Olivier J. and Torreele, Els and McKee, Martin picture_as_pdf
  • Investments in research and development for supplemental drug indications:implications for drug price negotiations. Vokinger, Kerstin N. and Perényi, Gellért and Wouters, Olivier J. picture_as_pdf
  • Lobbying expenditures and campaign contributions by the pharmaceutical and health-product industry in the United States, 1999- 2018. Wouters, Olivier J. picture_as_pdf
  • Lobbying in US health care:lessons from the field of oncology. Wouters, Olivier J. picture_as_pdf
  • Low- and middle-income countries experienced delays accessing new essential medicines, 1982–2024. Wouters, Olivier J. and Kuha, Jouni picture_as_pdf
  • Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021. Feldman, William B. and Tu, S. Sean and Alhiary, Rasha and Kesselheim, Aaron S. and Wouters, Olivier J. picture_as_pdf
  • Measuring health science research and development in Africa:mapping the available data. Wenham, Clare and Wouters, Olivier J. and Jones, Catherine M. and Juma, Pamela A. and Mijumbi-Deve, Rhona M. and Sobngwi-Tambekou, Joëlle L. and Parkhurst, Justin picture_as_pdf
  • Medical savings accounts: assessing their impact on efficiency, equity, and financial protection in health care. Wouters, Olivier J. and Cylus, Jonathan and Yang, Wei and Thomson, Sarah and McKee, Martin
  • Medicare drug price negotiation:the complexities of selecting therapeutic alternatives for estimating comparative effectiveness. Hernandez, Inmaculada and Cousin, Emma and Wouters, Olivier J. and Gabriel, Nico and Cameron, Teresa and Sullivan, Sean D. picture_as_pdf
  • Multi-country collaboration in responding to global infectious disease threats:lessons for Europe from the COVID-19 pandemic. Jit, Mark and Ananthakrishnan, Aparna and McKee, Martin and Wouters, Olivier J. and Beutels, Philippe and Teerawattananon, Yot picture_as_pdf
  • Pharmaceutical regulation in 15 European countries: review. Panteli, Dimitra and Arickx, Francis and Cleemput, Irina and Dedet, Guillaume and Eckhardt, Helene and Fogarty, Emer and Gerkens, Sophie and Henschke, Cornelia and Hislop, Jennifer and Jommi, Claudio and Kaitelidou, Daphne and Kawalec, Pawel and Keskimäki, Ilmo and Kroneman, Madelon and Lopez Bastida, Julio and Pita Barros, Pedro and Ramsberg, Joakim and Schneider, Peter and Spillane, Susan and Vogler, Sabine and Vuorenkoski, Lauri and Wallach Kildemoes, Helle and Wouters, Olivier J. and Busse, Reinhard
  • Price benchmarks of drugs selected for medicare price negotiation and their therapeutic alternatives. Hernandez, Inmaculada and Cousin, Emma M. and Wouters, Olivier J. and Gabriel, Nico and Cameron, Teresa and Sullivan, Sean D. picture_as_pdf
  • Private financing of health care in times of economic crisis: a review of the evidence. Wouters, Olivier J. and McKee, Martin
  • QALYs in cost-effectiveness analysis: an overview for cardiologists. Wouters, Olivier J. and Naci, Huseyin and Samani, Nilesh J
  • Quantifying research and development expenditures in the drug industry. Wouters, Olivier J. and Kesselheim, Aaron S. picture_as_pdf
  • Research and development costs of new drugs:in reply. Wouters, Olivier J. and McKee, Martin and Luyten, Jeroen
  • Resource planning for Neglected Tropical Disease (NTD) Control Programs: feasibility study of the Tool for Integrated Planning and Costing (TIPAC). Wouters, Olivier J. and Downs, Philip W. and Zoerhoff, Kathryn L. and Crowley, Kathryn R. and Frawley, Hannah and Einberg, Jennifer and Chu, Brian K. and Brady, Molly A. and Oscar, Roland and Jeudi, Mireille and Desormeaux, Anne-Marie and Coly, Karleen and Direny, Abdel N. and Thakur, Garib D. and Pokharel, Raj K. and Sharma, Shekhar and Raman, Dharmpal P. and Sesay, Santigie and Sonnie, Mustapha and Kilembe, Bernard and Mwingira, Upendo and Yajima, Aya
  • Rethinking the appraisal and approval of drugs for type 2 diabetes. Naci, Huseyin and Lehman, Richard and Wouters, Olivier J. and Goldacre, Ben and Yudkin, John S
  • Risks to health and the NHS in the post-Brexit era. van Schalkwyk, May C.I. and Jarman, Holly and Hervey, Tamara and Wouters, Olivier J. and Barlow, Pepita and McKee, Martin
  • Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving Food and Drug Administration accelerated approval. Naci, Huseyin and Wouters, Olivier J. and Gupta, Radhika and Ioannidis, John P. A.
  • Transferable exclusivity extensions to stimulate antibiotic research and development:what is at stake? Anderson, Michael and Wouters, Olivier J. and Mossialos, Elias picture_as_pdf
  • Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform. Wouters, Olivier J. and Kanavos, Panos
  • Wat kost onderzoek en ontwikkeling van een medicijn? Een oproep tot meer transparantie. Luyten, Jeroen and McKee, Martin and Wouters, Olivier J. picture_as_pdf
  • An assessment of the methodological quality of published network meta-analyses: a systematic review. Chambers, James D. and Naci, Huseyin and Wouters, Olivier J. and Pyo, Junhee and Gunjal, Shalak and Kennedy, Ian R. and Hoey, Mark G. and Winn, Aaron and Neumann, Peter J.
  • A comparison of generic drug prices in seven European countries: a methodological analysis. Wouters, Olivier J. and Kanavos, Panos
  • The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period. Wouters, Olivier J. and Sandberg, Dale M. and Pillay, Anban and Kanavos, Panos picture_as_pdf
  • The launch of the EU Health Emergency Preparedness and Response Authority (HERA):improving global pandemic preparedness? Wouters, Olivier J. and Forman, Rebecca and Anderson, Michael and Mossialos, Elias and McKee, Martin picture_as_pdf
    • Chapter
  • Pharmaceutical parallel trade: legal, policy, and economic issues. Kanavos, Panos and Wouters, Olivier J.
  • Understanding the role of governance in the pharmaceutical sector: from laboratory to patient. Cylus, Jonathan and Wouters, Olivier J. and Kanavos, Panos
    • Conference or Workshop Item
  • Competition issues in the distribution of pharmaceuticals. Kanavos, Panos and Wouters, Olivier J.
  • Concurrence dans la distribution de produits pharmaceutiques. Kanavos, Panos and Wouters, Olivier J.
    • Report
  • Incentivizing nutrition: how to apply incentive mechanisms to accelerate improved nutrition outcomes: a practitioner’s compendium. Laviolette, Luc and Gopalan, Sudararajan and Elder, Leslie and Wouters, Olivier J.
  • Incentivizing nutrition: incentive mechanisms to accelerate improved nutrition outcomes. Laviolette, Luc and Gopalan, Sudararajan and Elder, Leslie and Wouters, Olivier J.
  • Pharmaceutical policies in Cyprus: a review of the current system and future options. Kanavos, Panos and Wouters, Olivier J.
    • Thesis
  • Essays on prices, volumes and policies in generic drug markets in high- and middle-income countries. Wouters, Olivier J. picture_as_pdf
    • Online resource
  • Primary health care should play bigger role in treating chronic kidney disease. Wouters, Olivier J. and Kanavos, Panos
    • ['eprint_typename_blog_post' not defined]
  • Vaccine nationalism risks prolonging the global pandemic. Wouters, Olivier J. picture_as_pdf